Please check the following:
- {{x.value}}
FREE membership
FREE membership
Join Intelligent Investor today
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
Please enter the 5 digit verification code sent to "{{user.DayPhone}}" Change number
We cannot send you a verification code via SMS to "{{user.DayPhone}}" Change number
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
Please enter your mobile number and press send to receive a text message with a verification code.
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
Thank you
We have sent you an email with the details of your registration.
Purchase order
Sign up
Log in
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Log in
Upgrade Today
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
{{eventFunction.Name}}
{{eventFunction.EventTypeName}}
{{eventFunction.StartDate}}
{{eventFunction.EventTimings}}
{{eventFunction.VenueName}}
{{ t.Cost === 0 ? "FREE" : "$" + t.Cost.toFixed(2) }}
Quantity *
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
Congratulations!
You now have free access to InvestSMART, we look forward to helping you on your financial journey.
You now have access to Free Eureka Report Insights, We look forward to helping you on your financial journey.
You now have access to Intelligent Investor Free Insights. We look forward to helping you build a market beating stock portfolio.
Looking for more…
Intelligent Investor Membership
15-day Free Trial
- Indepth analysis of ASX listed shares
- BUY, Hold and Sell Recommendations
- Ideas Lab
- Special Reports
No thanks
Looking for more…
Eureka Report Membership
15-day Free Trial
- Alan Kohler’s Weekend Briefing
- Interviews with CEO’s & top influencers
- Money Cafe and Talking Finance
- Super Advice and Q&A with Ask Alan
No thanks
Clinuvel Pharmaceuticals Limited (ASX: CUV) - Share Price and Research
- Current share price for CUV : $15.290
Clinuvel Pharmaceuticals Limited (CUV), an ASX-listed company, is a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for the general population.
CUV General Information +
| ASX Code | CUV |
| Website | http://www.clinuvel.com |
| Industry/Sector | Biotechnology |
| Market Cap ($M) | 766 |
| CUV Share Price | $15.290 |
| Day High | $15.300 |
| Day Low | $14.940 |
| Last Close | $15.290 |
| CUV Share Price Movement | - ( No change ) |
Prices as at 16:40, 18 Apr 2024
+Security prices are delayed by at least 20 minutes and are indicative only.
Recommendation
Clinuvel Pharmaceuticals Limited - CUV
Current price
$15.29 at 16:40 (18 April 2024)
Price at review
$23.43 at (25 February 2023)
Business Risk
Share Price Risk
All Prices are in AUD ($)
CUV Related Research
Clinuvel Pharmaceuticals Limited (CUV) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|---|---|---|---|---|---|---|
| HFResult | 5¢ | 100% | 5 Sep 2023 | 20 Sep 2023 | $15.290 | $15.280 | 0.33% |
| HFResult | 4¢ | 100% | 6 Sep 2022 | 21 Sep 2022 | $15.290 | $15.280 | 0.33% |
| HFResult | 2.5¢ | 0% | 2 Sep 2021 | 17 Sep 2021 | $15.290 | $15.280 | 0.33% |
See all dividends from Clinuvel Pharmaceuticals Limited (CUV) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Clinuvel Pharmaceuticals Limited (CUV) Recent ASX Announcements
| Headline | Annoucement date/time+ | Price at announcement+ | Current price+ | Price 7D Avg | Gain/Loss |
|---|---|---|---|---|---|
| Change to executive management | 15 Apr 2024 10:01AM | $15.170 | $15.290 | $15.280 | risen by 0.79% |
| Update - Notification of buy-back - CUV | 12 Apr 2024 9:04AM | $15.280 | $15.290 | $15.280 | risen by 0.07% |
| Update - Notification of buy-back - CUV | 10 Apr 2024 9:16AM | $15.250 | $15.290 | $15.280 | risen by 0.26% |
- + Company announcements and prices are delayed by at least 20 minutes. Prices are indicative only.
See all ASX announcements from Clinuvel Pharmaceuticals Limited (CUV) or use our ASX Announcements tool to search for announcements across all ASX-listed securities.
CUV Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025F | $41.52 | $82.36 | 15.70% | 18.56 | 8.00 | 0.52% | 100.0% |
| 2024F | $35.90 | $71.21 | 22.60% | 21.47 | 7.00 | 0.46% | 100.0% |
| 2023A | $30.09 | $58.08 | 47.50% | 34.33 | 5.00 | 0.25% | 100.0% |
CUV Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 F | 2025 F | 2023 A | 2024 F | 2025 F | 2023 A | 2024 F | 2025 F | ||
| CSL (CSL) | $131,744M | -0.0712 | 0.1072 | 0.1864 | 39.8999 | 36.0370 | 30.3755 | 1.31% | 1.23% | 1.38% |
| Clinuvel Pharmaceuticals (CUV) | $759M | 0.4665 | 0.2049 | 0.1566 | 25.6345 | 21.2751 | 18.3949 | 0.33% | 0.46% | 0.53% |
| Imugene (IMU) | $608M | 1.3429 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Mesoblast (MSB) | $856M | -0.1037 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Telix Pharmaceuticals (TLX) | $4,144M | -1.3767 | 0.0000 | 0.0000 | 99.3661 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
CUV Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.50 | 22.20 | 4.59 | 1.23 |
| Market | 0.53 | 15.30 | 1.11 | 1.01 |
| Sector | 1.26 | 21.30 | 1.92 | 0.98 |
CUV Directors
| Name | Position | Start Date |
|---|---|---|
| Dr Philippe J Wolgen | Chief Executive Officer, Managing Director | 1 Oct 2005 |
| Dr Jeffrey Rosenfeld | Non-Executive Chairman, Non-Executive Director | 26 Nov 2019 |
| Ms Brenda Mary Shanahan | Non-Executive Director | 6 Feb 2007 |
| Mrs Susan (Sue) Smith | Non-Executive Director | 23 Sep 2019 |
| Dr Karen Agersborg | Non-Executive Director | 29 Jan 2018 |
Clinuvel Pharmaceuticals Limited (CUV) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 19 Sep 2023 | WOLGEN, Philippe | Buy | Direct Shares | 1,850 | $16.116 | $29,813.860 |
| 26 Jun 2023 | WOLGEN, Philippe | Buy | Direct Shares | 1,532 | $17.720 | $27,147.330 |
| 4 Nov 2022 | ROSENFELD, Jeffrey | Buy | Indirect Shares | 300 | $19.440 | $5,832.000 |
See all changes in directors' interest & trades for Clinuvel Pharmaceuticals Limited (CUV) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
CUV Management
| Name | Position |
|---|---|
| Darren Keamy | Chief Finance Officer,Company Secretary |
CUV Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Clinuvel Pharmaceuticals Limited (CUV). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 4,296,472 (8.70%) | The Bank of New York Mellon Corporation |
| 3,122,247 (6.73%) | Dr Philippe Jacques Wolgen |
| 2,340,824 (6.13%) | Ender 1, LLC and SNP Ventures Group Member |
CUV Calendar of Events
| Date | Event |
|---|---|
| 20 February 2025 | Report (Interim) |
| 27 August 2024 | Report (Annual) |
| 27 August 2024 | Report (Prelim) |
FAQs about Clinuvel Pharmaceuticals Limited (CUV)
What is the current share price of Clinuvel Pharmaceuticals Limited (CUV)?
Clinuvel Pharmaceuticals Limited's (CUV) current share price is $15.29. This constitutes a price movement of 0.07% when compared to the share price 7 days ago and is -28.22% below CUV's 12-month high of $21.30 per share. Prices are delayed by at least 20 minutes.
What is the share price movement for Clinuvel Pharmaceuticals Limited (CUV)?
Relative to the previous close share price of $15.29, Clinuvel Pharmaceuticals Limited's (CUV) current share price of $15.29 constitutes a movement of or 0%. Clinuvel Pharmaceuticals Limited's (CUV) share price movement is 0.07% when compared to 7 days ago and is -28.22% below CUV's 52-week high of $21.30.
What is the 52-week high share price for Clinuvel Pharmaceuticals Limited (CUV)?
Clinuvel Pharmaceuticals Limited's (CUV) 52-week high is $21.30 which was reached on 25 Aug 2023. Relative to this, CUV's current share price of $15.29 constitutes a -$6.01 or -28.22% drop since that high of $21.30 per CUV share.
What is the 52-week low share price for Clinuvel Pharmaceuticals Limited (CUV)?
Clinuvel Pharmaceuticals Limited's (CUV) 52-week low is $13.20 which was reached on 13 Mar 2024. Relative to this, CUV's current share price of $15.29 constitutes a $2.09 or 15.83% gain since that low of $13.20 per CUV share.
What is the daily average trading volume for Clinuvel Pharmaceuticals Limited (CUV)?
Over the last 12 months, Clinuvel Pharmaceuticals Limited (CUV) has a daily average trading volume of 88,328 CUV shares per day.
What is the dividend yield for Clinuvel Pharmaceuticals Limited (CUV)?
Clinuvel Pharmaceuticals Limited (CUV) has a current dividend yield of n/a this year. Last year's dividend yield was 0.30%. The dividend yield for CUV is a ratio that tells you the percentage of Clinuvel Pharmaceuticals Limited's (CUV) share price that it pays out in dividends each year.
What was Clinuvel Pharmaceuticals Limited (CUV) last dividend payment?
Clinuvel Pharmaceuticals Limited (CUV) last dividend payment was $0.05 per share and was paid on 20 Sep 2023. This last CUV dividend included 100% franking.
What is the franking level for Clinuvel Pharmaceuticals Limited (CUV)?
Clinuvel Pharmaceuticals Limited (CUV) has a franking level of 100%. Franking represents the tax Clinuvel Pharmaceuticals Limited (CUV) has already paid on any profit it distributes to shareholders as a dividend.
When does Clinuvel Pharmaceuticals Limited (CUV) release its next Annual Report?
Clinuvel Pharmaceuticals Limited (CUV) will release its next Annual Report on 27 August 2024. Clinuvel Pharmaceuticals Limited's (CUV) last annual report was released on 29 Aug 2023. Click here to view Clinuvel Pharmaceuticals Limited's (CUV) last annual report.
In which sector is Clinuvel Pharmaceuticals Limited (CUV) classified?
Clinuvel Pharmaceuticals Limited (CUV) is classified as Health Care. Other companies in this sector include CSL Limited (CSL), Cochlear Limited (COH), ResMed Inc. (RMD), and Fisher & Paykel Healthcare Corporation Limited (FPH).
What is the price-to-earnings (P/E) ratio for Clinuvel Pharmaceuticals Limited (CUV)?
The price-to-earnings (P/E) ratio for Clinuvel Pharmaceuticals Limited (CUV) is 22.2. The price-to-earnings ratio, also known as P/E ratio, P/E, or PER, is the ratio of Clinuvel Pharmaceuticals Limited's (CUV) share price to its earnings per CUV share.
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
